STOCK TITAN

Surmodics Inc - SRDX STOCK NEWS

Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.

Surmodics Inc. (SRDX) drives innovation in medical device coatings and diagnostic solutions through partnerships with global healthcare leaders. This news center delivers verified updates on the company's financial developments, regulatory milestones, and technological breakthroughs shaping patient care.

Find curated press releases detailing SRDX's advancements in vascular intervention systems, diagnostic platform enhancements, and strategic collaborations. Track earnings reports and product launch announcements that highlight the company's transition from coating pioneer to comprehensive medical solution developer.

Our repository includes updates on FDA clearances, clinical study results, and manufacturing expansions critical for assessing SRDX's market position. Discover how the company's surface modification expertise addresses challenges in drug delivery systems and in-vitro diagnostics.

Bookmark this page for ongoing insights into Surmodics' role in medical innovation. Return regularly to stay informed about developments impacting the future of minimally invasive therapies and diagnostic accuracy.

Rhea-AI Summary
Surmodics, Inc. (SRDX) to Participate in 35th Annual Piper Sandler Healthcare Conference. The company's management will present at the conference on November 28, 2023, and a live webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
-
Rhea-AI Summary
SRDX: Surmodics Reports Strong Financial Results and Fiscal 2024 Guidance, Announces New Product Launches and Clinical Trial Data
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
-
Rhea-AI Summary
Surmodics, Inc. will present 24-month data from the SWING Trial, evaluating the Sundance™ Sirolimus Drug-Coated Balloon's safety and performance in treating occlusive lesions in the infra-popliteal arteries. The trial reports an 8.3% major adverse event rate at 6 months and an 80% target lesion primary patency rate at 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. has launched Preside hydrophilic coatings, its most advanced medical device coating technology. The coatings offer low-friction and low-particulate generation, improving distal access for neurovascular applications and crossing for challenging coronary lesions. The coatings are formulated to balance enhanced lubricity and coating durability. Surmodics has secured the first 510(k) device clearance for this technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. to release Q4 2023 financial results on November 8
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
-
Rhea-AI Summary
Surmodics, Inc. (SRDX) reported a total revenue of $52.5 million, a 111% increase year-over-year, with a GAAP Diluted EPS of $0.52. The company obtained FDA premarket approval for the SurVeil DCB, leading to a $27 million milestone payment, and received FDA 510(k) clearance for its Pounce LP Thrombectomy System. Medical Device revenue grew by 163%, while In Vitro Diagnostics revenue decreased by 12%. Surmodics now expects fiscal year 2023 total revenue to range from $130 million to $132 million, representing an increase of 30% to 32% compared to the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
Surmodics Inc

Nasdaq:SRDX

SRDX Rankings

SRDX Stock Data

406.58M
13.74M
3.41%
87.05%
1.9%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE